Category: Ibogaine News & Articles

Revolutionizing Addiction Treatment: The Role of Ibogaine and Casa Santa Isabel’s Pioneering Efforts

In a groundbreaking shift within the realm of addiction treatment, ibogaine, a naturally occurring psychoactive substance found in the African iboga plant, is making headlines for its potential to significantly disrupt traditional approaches to opioid addiction recovery. A recent article in the New York Times highlights the growing interest in ibogaine’s unique ability to alleviate withdrawal symptoms and reduce cravings, offering hope to those trapped in the cycle of addiction.

Amidst the burgeoning field of psychedelic-assisted therapies, Casa Santa Isabel, located in the picturesque Baja California, Mexico, emerges as a beacon of hope and innovation. As one of the most respected and legitimate clinics for ibogaine therapy in Mexico, Casa Santa Isabel has dedicated itself to harnessing the transformative power of ibogaine under the guidance of licensed medical professionals.

The clinic’s approach is deeply rooted in scientific research and holistic care, ensuring that each treatment is tailored to the individual’s needs, providing not just a temporary reprieve but a profound, life-altering experience. With a focus on safety, compassion, and efficacy, Casa Santa Isabel stands at the forefront of ibogaine therapy, contributing to the growing body of evidence supporting its effectiveness in addiction treatment.

Ibogaine therapy at Casa Santa Isabel is not merely about substance cessation; it’s a comprehensive journey towards healing and self-discovery. Patients are supported through a meticulously structured program that addresses the psychological, physical, and spiritual facets of addiction, fostering an environment where profound transformation can occur.

As the world begins to recognize the potential of psychedelic-assisted therapies, Casa Santa Isabel’s work with ibogaine offers a compelling case study in the power of alternative treatments. The clinic’s commitment to research, patient care, and therapeutic innovation has solidified its status as a leading figure in the global movement towards more effective and compassionate addiction treatment solutions.

For those seeking a path out of addiction, Casa Santa Isabel represents a fusion of cutting-edge therapy and heartfelt care, embodying the promise of a future where healing and hope are within reach for everyone affected by opioid addiction.

Psychedelics can change humanity for the better its time to unlock their power

MAPS (Multidisciplinary Association for Psychedelic Studies) is a non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics. Rick Doblin is a researcher at MAPS, and in “Psychedics can change humanity for the better. It’s time to unlock their power,” he delivers one of the most compelling cases for a range of psychedelics in helping those suffering from mental health and addiction issues. 

Doblin and his team work primarily with MDMA, ketamine, psilocybin, and ibogaine. As Doblin rightly states, indigenous communities worldwide have used psychedelics for hundreds, if not thousands of years in spiritual ceremonies and for healing. MAPS collaborates with researchers to facilitate the studies of psychedelic-assisted therapy with the hope that these interventions eventually become mainstream. MAPS research has found great effectiveness with ibogaine to treat opioid use disorder.   

Read full article here: https://www.theguardian.com/commentisfree/2021/nov/26/psychedelics-can-change-humanity-for-the-better-its-time-to-unlock-their-power

Ibogaine for addiction treatment

In 1962, a prominent scientist by the name of Howard Lotsof and his six friends decided to ingest ibogaine powder. The reason why? They were struggling mightily with heroin addiction and were on their last legs. The result – five of the six immediately quit heroin. 

Far from a robust longitudinal study, the results fascinated many. Fast-forward to the present and we know ibogaine has the potential to ameliorate a host of maladies. We’re treated to a comprehensive summary of the future of ibogaine in  “Ibogaine Use in Addiction Treatment: An Overview.” The global drug addiction treatment market is expected to reach a staggering $37.7 billion by 2027. It is hard to find anyone who does not know someone struggling with an addiction. It is for this reason that ibogaine is now on the radar of leading life-science firms.

Read full article here: https://investingnews.com/ibogaine-for-addiction-treatment/

What if everyone took psychedelics

Psychedelics have a long history in popular culture. Typically viewed as counter-culture, primarily due to their Schedule-1 classification in the US and a Class-A classification in the UK, psychedelics are not entirely legal as any savvy reader could tell you. With that said, we have certainly witnessed waves of psychedelic renaissances over the years. Yet, it would appear that the last 5 years have been different. 

As Ed Prideaux details in “The worldview-changing drugs poised to go mainstream,” the difference we’re experiencing today is the psychiatric acceptance of psychedelics like ibogaine to treat a range of conditions: childhood autism, depression, criminal recidivism, schizophrenia, and alcoholism. A mind-boggling 6,000 studies covering 40,000 plus patients have been completed and the data could not be clearer.

Read full article here: https://www.bbc.com/future/article/20210906-what-if-everyone-took-psychedelics

Osoyoos indian band eyes cutting edge drug treatment centre

Partnerships exist in all walks of life. But a collaborative project between the Osoyoos Indian Band (OIB) and a company called Universal Ibogaine might be the first of its kind. 

Ibogaine has been a staple of many West African communities. Derived from the iboga shrub, its history as a spiritual sacrament is well-founded. But it wasn’t until the 1960s that practitioners began to experiment with ibogaine’s psychedelic components to treat a wide range of mental health and addiction issues.

Universal Ibogaine trades on the TSX Venture Exchange and the objective of the OIB joint venture is to build out an ibogaine center detox clinic. In “Osoyoos Indian Band eyes cutting-edge drug treatment centre,” author Joe Fries details this novel partnership. The opioid crisis claimed a shocking 2,224 lives in B.C. in 2021. Both entities feel ibogaine can play a critical role in treating opioid addiction, serving as a viable alternative to the more standard opioid substitution therapies.

Read the full article here: https://vancouversun.com/news/local-news/osoyoos-indian-band-eyes-cutting-edge-drug-treatment-centre

Psychedelic Interest Booms

Despite global COVID shutdowns and declines in medical research funding not related to the pandemic, interest in psychedelic use to treat addictions and other psychological issues is booming.   

The rise in popularity is happening in the business sector and beyond. While specific industries suffered economic blows due to COVID, notable psychedelic companies either went public or secured millions in funding. Currently, the U.S. Food and Drug Administration is conducting clinical trials involving psychedelic substances such as ibogaine, ketamine, and psilocybin. At the moment, ibogaine, a natural extract used in various countries to treat addiction, is a Schedule 1 drug and not approved for medical use in the United States.

There may not be a more optimal time to explore the therapeutic power of ibogaine. Over 15 million Americans suffer from depression, and some forms of depression have proven resistant to treatment. Millions suffer from substance addiction and co-occurring disorders.  

Read the full article here: https://www.forbes.com/sites/forbesagencycouncil/2020/06/09/why-the-future-of-mental-health-care-may-lie-in-psychedelics/?sh=63f8f5c55bac

Scientists Develop Synthetic Form of Ibogaine

University of California, Davis researchers have created a non-hallucinogenic version of ibogaine. The new substance could prove just as effective as the psychedelic original used to treat addiction and psychological illnesses such as depression and post-traumatic stress disorder.

David Olson, an assistant professor of chemistry at UC Davis, detailed the discovery in the December 2020 issue of Nature.   

In the study, a series of rodent experiments showed that mice decreased their alcohol consumption and experienced a delayed opiate relapse when given the non-hallucinogenic Tabernanthalog (TBG). The synthetic version is water-soluble and has fewer adverse effects than ibogaine. Olson says he’s optimistic that TBG can treat addiction and many illnesses related to addiction, such as depression and anxiety.

Read the full article here: https://www.ucdavis.edu/news/new-compound-related-psychedelic-ibogaine-could-treat-addiction-depression

Psychedelic Drug Attracts Corporate Attention

In the United States, over 2 million Americans suffered from opioid addiction in 2018. With relapse rates of traditional rehabilitative models averaging at about 50%, companies have positioned themselves within the psychedelic drug sector to bring a different therapeutic approach.

Companies such as ATAI Sciences and DemeRx are investigating ibogaine, a natural extract found in western Central Africa that has proven effective in reducing opioid withdrawal symptoms and cravings. Researchers also found that the same substance lessens depression that accompanies addiction. Despite the positive effects, ibogaine continues to be classified as a Schedule 1 drug not allowed for medical use in the United States. Regardless of the status, researchers continue to study precisely how ibogaine affects the brain and delivers relief to those suffering from addiction. It is believed that ibogaine affects neurotransmitter systems, including serotonin, NMDA, and opioid receptors.

Read the full article here: https://www.epmmagazine.com/pharmaceutical-industry-insights/how-psychedelic-medicine-is-being-used-in-the-fight-to-end-o/

Ibogaine Attracts Addiction Research

Researchers continue to examine the therapeutic properties of ibogaine as it proves effective in addiction rehabilitation. Countries such as New Zealand, Brazil, and South Africa allow it for medical use. In the United States, ibogaine is a Schedule 1 substance, which means it is not approved for medical use. 

Ibogaine is an indole alkaloid produced by the Taberna iboga shrub native to West Africa. Traditionally, consumers used the substance to reduce fever, boost sexual arousal, and improve health. Specifically, it has been found to bring on a psychedelic experience in larger doses, while decreasing opioid withdrawal symptoms and disrupting cravings. Researchers have also shown it to be effective in combatting depression and alcohol abuse. Like with all drugs, care must be exercised when using ibogaine. It has been found to potentially cause paralysis, heart or pulmonary failure, and seizures in rare cases.

Read the full article here: https://www.medicalnewstoday.com/articles/ibogaine-for-addicition

The Promise of Ibogaine

Traditional rehabilitative models are failing to deliver results to those trying to beat chronic drug abuse. Some are hailing the increasing popular extract ibogaine for its suppressive effects on withdrawal symptoms and ultimately, addiction.

Ibogaine, derived from a central west African shrub, is a psychedelic drug that has proven effective in treating alcohol, heroin, and opioid addiction in treatment centers worldwide. Scientists continue to study ibogaine to unlock its therapeutic power. One theory researchers have for ibogaine’s effectiveness is that it may increase brain neuron growth and plasticity, which is the brain’s ability to remodel itself. While human clinical trials are underway and pharmaceutical companies and government agencies worldwide continue to investigate ibogaine’s seemingly anti-addiction properties, some U.S. military veterans have found relief using the psychedelic drug. 

Read the full article here: https://time.com/5951772/ibogaine-drug-treatment-addiction/